BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, July 16, 2026
Home » Blogs » BioWorld MedTech Perspectives » Researchers pitch alternative treatment method for migraines

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Researchers pitch alternative treatment method for migraines

March 15, 2015
By Omar Ford

SIRcorrect

Earlier this month, I had the distinct pleasure of having a sit-down interview with Kenneth Mandato, the lead researcher for the migraine study and an interventional radiologist at Albany medical center, during the Society of Interventional Radiologists Annual meeting held here in Atlanta. During the interview we discussed the prevalence of migraines and a rather old (but underutilized) technique to treat these conditions. Mandato and a team of researchers from Albany Medical Center and the State University New York Empire State College (Saratoga Springs, New York), used a technique called image-guided intranasal sphenopalatine ganglion (SPG) blocks to give patients enough ongoing relief that they required less medication to relieve migraine pain.

Mandato said that the study shows that before treatment, patients reported a visual analogue scale of 8.25 with scores greater than four at least 15 days per month. The day after the SPG block patients' visual analogue scores were cut in half, to an average of 4.10 Thirty days after the procedure patients reported an average score of 5.25 a 36% decrease from pretreatment. About 88% of patients indicated that they required less or no migraine medication for ongoing relief.

Mandato seemed pretty happy about the results and the potential to do even more trials in the future to bolster the results. What was so impressive was the number of calls and media requests Mandato managed during his time at the conference. Migraines are a hot topic. Here's hoping interest in Mandato's work continues.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 16, 2026.
  • AI-generated  illustration of a neuron with tau protein aggregation

    AAIC 2026: Age of amyloid is being joined by time of tau

    BioWorld
    The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
  • Senior medical exam

    Celia trial: data strong, analysts skeptical

    BioWorld
    Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 14, 2026
  • Illustration of T cells attacking cancer

    GABA signaling linked to immune resistance in some tumors

    BioWorld
    Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing